Table of Contents Table of Contents
Previous Page  744 / 812 Next Page
Information
Show Menu
Previous Page 744 / 812 Next Page
Page Background

S740

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1224

Radiotherapy and treatment of

cervical cancer – sexuality

implications

A. Fornelos

, P. Macedo , S. Nunes , A. Figueiredo , M. Silva ,

M. Viseu

Centro Hospitalar Trás-os-Montes e Alto Douro, Psiquiatria e Saúde

Mental, Vila Real, Portugal

Corresponding author.

Introduction

Cancer of the uterine cervix represents 10%ofmalig-

nant tumors affecting women. Despite occupying fifth place in the

global mortality rate it is described with the highest healing poten-

tial. One of the most used treatments is radiotherapy, which has

a particularly significant impact on women’s quality of life, espe-

cially in their sexuality. Biological and psychic factors are suggested

as possible etiologies for sexual dysfunction situations. Changes in

body image may arouse feelings of shame and low self-esteem. In

what concerns biology, vaginal stenosis is referred as a cause of

vaginism and vaginal bleeding, with consequent decrease in libido

and pleasure.

Objective

Describe the implications in the sexuality of women

with cancer of the uterine cervix after radiotherapy.

Methods

A literature search using the PubMed and Scielo

databases of scientific articles published in the last 10 years.

Results

In the literature, there are significant changes in sex-

ual behavior in women with cervical cancer in the period after

radiotherapy. A large percentage reveals sexual abstinence and

an equally significant part presents sexual dysfunction caused by

lack of lubrication, arousal and orgasm. Moreover, it is reported

decreased libido and sexual pleasure, vaginal bleeding and vagin-

ism. On the other hand, there is a small account of cases in which

it is mentioned increase libido and pleasure.

Conclusion

Despite the high probability of healing this disease,

the patients’ quality of life after advanced stages of radiotherapy,

should be a source of concern, especially with regard to sexuality.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2209

EV1225

Premature ejaculation – how to

treat?

A. Fornelos

, P. Macedo , F. Veríssimo , M. Viseu

Centro Hospitalar Trás-os-Montes e Alto Douro, Psiquiatria e Saúde

Mental, Vila Real, Portugal

Corresponding author.

Introduction

Premature ejaculation (PE) corresponds to “a per-

sistent or recurring ejaculation pattern that occurs during sexual

activity with a partner approximately 1minute after vaginal pen-

etration and before the person wishes to”. It affects 5–20% of

men, having its origin in psychological factors and with impor-

tant biological contribution. It is considered generalised, when not

confined to certain patterns of stimulation, situations, or part-

ners, or may be situational. It may occur soon after the onset

of sexual activity (primary) or after a normal sexual functioning

(acquired). Primary EP is associated with the hyposensitivity 5-

HT2C receptors and/or hypersensitivity 5-HT1A receptors. High

performance anxiety levels are related to acquired EP. Increasing

this physiological knowledge has enabled significant advances in

treatment.

Objective

Approach the therapeutic options of EP and its pecu-

liarities.

Methods

Literature review of articles published in the last five

years, using the PubMed and Scielo databases.

Results

At present, the approaches include psychosexual coun-

seling, behavioral and pharmacotherapy. Among the most

popular drugs, antidepressants stand out, particularly dapoxe-

tine, the first medication specifically approved. Local anesthetics,

phosphodiesterase-5 inhibitors and tramadol are also used.

Acupuncture is suggested as a useful therapeutic, but needs more

research.

Conclusion

The behavioral therapies are referred to as first-line

treatment in the long-term, associated or not with medication.

Dapoxetine is the preferred symptomatic treatment. However, a

holistic approach, including psychotherapy and sex therapy, is the

most beneficial modality for sexual and marital relationship.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2210

EV1226

Sexual function in schizophrenia

D. Lin

Napa, CA, USA

Objective

This study surveys patients with schizophrenia or

schizoaffective disorder, to understand the relationship between

sexual function and treatment with antipsychotic medication. The

study compares patients on single versus multiple antipsychotics

as well differences between first and second-generation agents.

Design and methods

Patients diagnosed with schizophrenia or

schizoaffective disorder are eligible. Once patients are evaluated to

ensure they meet enrollment criteria and are consented, they are

administered the Positive and Negative Syndrome Scale (PANSS),

Abnormal Involuntary Movement Scale (AIMS), and either the

International Index of Erectile Function for men, or the Female Sex-

ual Function Index for women. Inclusion criteria include age 18–65,

able to participate in a structured interview, fulfill DSM-IV criteria

for Schizophrenia or Schizoaffective disorder, and on stable doses of

one or more antipsychoticmedications for at least sixweeks. Exclu-

sion criteria include patients taking Selective Serotonin Reuptake

Inhibitors (SSRIs), and inability to provide informed consent.

Results

Patients taking typical antipsychotic had marginally

worse score on sexual function scale. Patients taking multiple

antipsychotics scored better on the sexual function scales. Those on

prolactin-sparing agents tended to rate sexual function as higher.

Clozapine was associated with more sexual dysfunction compared

to other antipsychotics. No trend noticed between PANSS scores

and sexual dysfunction. No trend noticed related to AIMS scores.

Conclusions

There is high prevalence of sexual dysfunction in

schizophrenic patients. Prolactin-sparing agents are associated

with less sexual dysfunction. There is an advantage to the use of

atypical antipsychotics.

Disclosure of interest

The author has not supplied his declaration

of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2211

EV1227

Sex addiction: Myth or reality

D. Lin

Napa, CA, USA

Objective

Since the concept of sexual addiction was first intro-

duced in the 1970’s, two schools of thought have emerged amongst

sexologists and mental health providers regarding whether hyper-

sexual behavior should be characterized as an addiction, or if it is

part of a co-existing psychiatric disorder. The objective of this study

is to help clarify this debate.

Method

A literature review was conducted to explore these

opposing viewpoints. Articles published from the year 2000 to

present relating to the topic of sex addiction, hypersexuality, sexual

compulsivity/impulsivity were reviewed to determine whether or

not hypersexual behavior can be characterized as an addiction or if

it can only co-exist with a current psychiatric disorder.